Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chad Glasser

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
The Pediatric Infectious Disease Journal|February 7, 2018
Randomized Multicenter Study Comparing Safety and Efficacy of Daptomycin Versus Standard-of-care in Pediatric Patients With Staphylococcal BacteremiaAntonio C Arrieta, John S Bradley, Myra W Popejoy, et al.
Clinical and Translational Science|April 29, 2023
First-in-human trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of zagociguat (CY6463), a CNS-penetrant soluble guanylyl cyclase stimulatorSebastiaan J W van Kraaij, Pim Gal, Laura G J M Borghans, et al.
British Journal of Clinical Pharmacology|July 25, 2023
Randomized placebo-controlled crossover study to assess tolerability and pharmacodynamics of zagociguat, a soluble guanylyl cyclase stimulator, in healthy elderlySebastiaan J W van Kraaij, Laura Borghans, Erica S Klaassen, et al.
Pediatrics|February 17, 2017
Daptomycin for Complicated Skin Infections: A Randomized TrialJohn Bradley, Chad Glasser, Hernando Patino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2016
The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell CarcinomaMartin H Voss, Rupal S Bhatt, Elizabeth R Plimack, et al.
Journal of Patient-Reported Outcomes|October 27, 2025
Signs, symptoms, and health-related quality of life in MELAS: measuring what's important from the patient and clinician perspectivesPaolo Medrano, Benjamin Banderas, Marisa Brimmer, et al.
Cancer|September 21, 2016
A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neckAntonio Jimeno, Marshall R Posner, Lori J Wirth, et al.
Cancer|April 6, 2019
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinomaMartin H Voss, Rupal S Bhatt, Nicholas J Vogelzang, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
The Pediatric Infectious Disease Journal|February 7, 2018
Randomized Multicenter Study Comparing Safety and Efficacy of Daptomycin Versus Standard-of-care in Pediatric Patients With Staphylococcal BacteremiaAntonio C Arrieta, John S Bradley, Myra W Popejoy, et al.
Clinical and Translational Science|April 29, 2023
First-in-human trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of zagociguat (CY6463), a CNS-penetrant soluble guanylyl cyclase stimulatorSebastiaan J W van Kraaij, Pim Gal, Laura G J M Borghans, et al.
British Journal of Clinical Pharmacology|July 25, 2023
Randomized placebo-controlled crossover study to assess tolerability and pharmacodynamics of zagociguat, a soluble guanylyl cyclase stimulator, in healthy elderlySebastiaan J W van Kraaij, Laura Borghans, Erica S Klaassen, et al.
Pediatrics|February 17, 2017
Daptomycin for Complicated Skin Infections: A Randomized TrialJohn Bradley, Chad Glasser, Hernando Patino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2016
The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell CarcinomaMartin H Voss, Rupal S Bhatt, Elizabeth R Plimack, et al.
Journal of Patient-Reported Outcomes|October 27, 2025
Signs, symptoms, and health-related quality of life in MELAS: measuring what's important from the patient and clinician perspectivesPaolo Medrano, Benjamin Banderas, Marisa Brimmer, et al.
Cancer|September 21, 2016
A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neckAntonio Jimeno, Marshall R Posner, Lori J Wirth, et al.
Cancer|April 6, 2019
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinomaMartin H Voss, Rupal S Bhatt, Nicholas J Vogelzang, et al.
Pageof 1